Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | KRAS | P01116 | 2/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 3/20 | 0.38 |
| ▸ | MMP1 | P03956 | 2/20 | 0.38 |
| ▸ | MMP3 | P08254 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | MMP7 | P09237 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11445440 | 0.89 | GRM5 (0.44) | SMN1; SMN2NPC1RAB9AHTR2CGAA | |
| SCHEMBL11453696 | 0.89 | SMN1; SMN2 (0.43) | SMN1; SMN2NPC1RAB9AHTR2CGAA | |
| SCHEMBL11445583 | 0.89 | HSD17B10 (0.42) | SMN1; SMN2NPC1RAB9AHTR2CGAA | |
| SCHEMBL11445289 | 0.89 | PTGDR2 (0.45) | SMN1; SMN2NPC1RAB9AHTR2CGAA | |
| SCHEMBL5872544 | 0.88 | HTR2C (0.47) | SMN1; SMN2NPC1RAB9AHTR2CGAA | |
| SCHEMBL5131797 | 0.88 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9AHTR2CGAA | |
| SCHEMBL11445480 | 0.86 | KMT2A (0.52) | SMN1; SMN2NPC1RAB9AHTR2CGAA | |
| SCHEMBL6740752 | 0.85 | HTR2C (0.46) | SMN1; SMN2NPC1RAB9AHTR2CGAA | |
| SCHEMBL25405608 | 0.85 | TDP1 (0.42) | SMN1; SMN2NPC1RAB9AHTR2CGAA | |
| SCHEMBL30816005 | 0.84 | SMN1; SMN2 (0.40) | SMN1; SMN2NPC1RAB9AGAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114096533-B | Tri-ring compound, pharmaceutical composition containing same, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-03-08 | — | — | CN | disclosed |
| WO-2021047406-A1 | TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2021-03-18 | — | — | WO | disclosed |
| WO-2021047406-A1 | TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2021-03-18 | — | — | WO | disclosed |
| US-20080188460-A1 | Tricyclic compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2008-08-07 | — | — | US | disclosed |
| US-6638934-B2 | 2,3,4,4a,5,6-hexahydro-1H-pyrazino(1,2-a)quinoxaline derivatives; treating depression, schizophrenia; (5-hydroxytryptamine=5HT) 5HT2a antagonist or a 5HT2c agonist | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-10-28 | — | — | US | disclosed |
| EP-1345942-A2 | PYRAZINOQUINOXALINE DERIVATIVES AS SEROTONIN AGONISTS AND ANTAGONISTS | Bristol-Myers Squibb Pharma Company (US) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002059127-A2 | PYRAZINOQUINOXALINE DERIVATIVES AS SEROTONIN AGONISTS AND ANTAGONISTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188460-A1 | Tricyclic compounds, a process for their preparation and pharmaceutical compositions containing them | BAX, BCL2, CASP3 | SMN1; SMN2 834/4885NPC1 218/4885RAB9A 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.